Nikolai Siebert

8PUBLICATIONS
28CO-AUTHORS
Radiation therapyGene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Neural engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 13, 2025
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Holger N Lode, Przemysław Holko, Aleksandra Wieczorek

|Aug 14, 2025
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Sascha Troschke-Meurer, Maxi Zumpe, Peter Moritz Ahrenberg

|Jul 08, 2025
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet

|Jul 14, 2023
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.

Holger N Lode, Ruth Ladenstein, Sascha Troschke-Meurer

|Jul 14, 2023
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.

Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke

|Apr 05, 2020
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.

Sascha Marx, Fabian Wilken, Isabel Wagner

Pageof 2

Frequent Collaborators

8 joint publications

Sascha Troschke-Meurer

6 joint publications

Holger N Lode

4 joint publications

Maxi Zumpe

2 joint publications

Madlen Marx